Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
Research output: Contribution to journal › Journal article › Research › peer-review
Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
|Journal||Scientific World Journal|
|Number of pages||4|
|Publication status||Published - 2012|